E528D9EE-41C3-4D4C-B16F-ABBDD6E31B84
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 156.11038107752955
- age_years
- 41
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.591
- MYC_TARGETS_V2+0.562
- E2F_TARGETS+0.561
- G2M_CHECKPOINT+0.560
- NOTCH_SIGNALING+0.551
- DNA_REPAIR+0.435
- MITOTIC_SPINDLE+0.366
- OXIDATIVE_PHOSPHORYLATION+0.362
- WNT_BETA_CATENIN_SIGNALING+0.362
- UNFOLDED_PROTEIN_RESPONSE+0.326
Top 10 suppressed
- MYOGENESIS-0.389
- COAGULATION-0.387
- KRAS_SIGNALING_DN-0.386
- INTERFERON_GAMMA_RESPONSE-0.339
- INTERFERON_ALPHA_RESPONSE-0.337
- IL6_JAK_STAT3_SIGNALING-0.327
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.321
- INFLAMMATORY_RESPONSE-0.316
- TNFA_SIGNALING_VIA_NFKB-0.316
- HYPOXIA-0.301
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 4938761D-0762-4984-A399-BC036D6D2140 | — | — | 0.954 |
| 2 | 30906368-89BC-42E0-8F7B-81B1DEDE812D | — | — | 0.932 |
| 3 | 6E8A9288-C2F1-4DDE-B52B-7656DB802FB4 | — | — | 0.928 |
| 4 | A85A0E3A-2CB9-40EB-80E9-125EC137151B | — | — | 0.927 |
| 5 | 0D600773-1B42-4F04-BCEA-39F658DF63F1 | — | — | 0.927 |
| 6 | E3A67B7B-7427-4C11-912B-166451072767 | — | — | 0.926 |
| 7 | 2C70D7BF-85C4-447B-B0F9-A129D6B49E77 | — | — | 0.926 |
| 8 | 5F991EDF-3871-4111-9A04-BF6CA02648CA | — | — | 0.924 |
| 9 | SRR934765 | — | — | 0.924 |
| 10 | SRR934879 | — | — | 0.922 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.591 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.562 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.561 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.560 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.551 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.435 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.366 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.362 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.362 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.326 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.304 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.236 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.218 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.179 | Inavolisib | — uncovered |
| PEROXISOME | 0.149 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.095 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.056 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.042 | Cobimetinib | — uncovered |
| ADIPOGENESIS | 0.038 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.022 | Inavolisib | — uncovered |